Medicinal Product Support in New Zealand
End-to-end Regulatory support from global experts

Greetings from Freyr, New Zealand

New Zealand is emerging as a high-opportunity market for pharmaceuticals, medical devices, consumer health products, food supplements, and Cosmetics. Companies planning drug registration in New Zealand must navigate a Regulatory system governed by the Medicines Act 1981 and Medicines Regulations 1984, while the government advances a new Medical Products Bill to modernize future regulation.

During this transition, Medsafe Regulatory requirements continue to evolve across clinical trials, pharmacovigilance, manufacturing, labeling, and advertising. Manufacturers entering the market must carefully manage compliance while aligning with updated Regulatory guidance.

Freyr provides New Zealand pharmaceutical Regulatory services and supports global companies with Regulatory intelligence, market entry planning, and compliance management, ensuring products remain aligned and competitive in the New Zealand market.

Medicinal Product Support in New Zealand - Overview

New Zealand is a well-regulated pharmaceutical market aligned with international regulators such as the FDA, EMA, Health Canada, and Australia’s TGA. This alignment allows manufacturers to leverage global data when pursuing drug registration in New Zealand.

The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) oversees medicine evaluation, approval, and monitoring.

Key Medsafe Regulatory requirements include:

• Submission of a New Medicine Application (NMA) in New Zealand
• Evidence demonstrating product quality, safety, and efficacy
• GMP compliance for medicines in New Zealand
• Local labeling and packaging compliance
• Appointment of a New Zealand sponsor

Freyr supports pharmaceutical, biotechnology, and generics manufacturers with Medsafe drug approval process management, Regulatory submissions, lifecycle management, and post-approval compliance to enable efficient pharmaceutical market entry in New Zealand.

Medicinal Product Classification in New Zealand

New Zealand classifies medicines based on the supply control and level of required supervision as defined in the Medicines Act 1981 and associated regulations:

• Prescription Medicines: Supplied only with a doctor's prescription.
• Restricted Medicines (Pharmacist-Only Medicines): Supplied by a pharmacist after consultation, without a prescription.
• Pharmacy-Only Medicines: Sold exclusively through pharmacies, no mandatory pharmacist consultation required.
• General Sale Medicines: Deemed safe for self-medication and available at general retail outlets.
  • Medicines not listed in the classification schedules are referred to as General Sale Medicines (Guideline on the Regulation of Therapeutic Products in New Zealand, 2023-2024).
• Controlled Drugs: Regulated under the Misuse of Drugs Act 1975 for substances with potential for dependence (Guidelines on the Regulation of Therapeutic Products in New Zealand: Overview of Regulation, 2024).
• The classification process is directed by the Medicines Classification Committee and changes are notified via the New Zealand Gazette (Medsafe, 2024 guidance).

Medicinal Product Registration & Approval in New Zealand

• Regulatory Pathways:
  • New Medicine Application (NMA): Primary route for new medicines not previously marketed.
  • Related Product Application: For related therapeutic products as clarified by Medsafe.
  • There is also a Verification Pathway for some applications, referencing overseas Regulatory approvals (Regulatory Impact Statement, 2025).
• Sponsor Obligations: Only a New Zealand-based sponsor or agent can submit and maintain an application (Guideline on the Regulation of Therapeutic Products in New Zealand, 2023).
• Dossier Requirements:
  • Includes detailed data on quality, safety, and efficacy.
  • Clinical evidence, GMP (Good Manufacturing Practice) compliance, labeling, and Consumer Medicine Information (CMI) are mandatory.
• Scientific Evaluation:
  • Medsafe evaluates submitted evidence against recognized standards and may request further data in several rounds.
  • Evaluation includes checking the quality of starting materials, manufacturing, quality assurance, and labeling based on New Zealand-specific criteria.
• Consent for Distribution: Approval (consent) is required before marketing, following a recommendation by Medsafe to the Minister or their delegate.
• Post-Approval Changes: Material changes to approved medicines are notified via:
  • Changed Medicine Notification (CMN)
  • Self-assessable changes
  • Approval for marketing updated products cannot proceed until consent for the change is given.
• Post-Market Surveillance:
  • All consented medicines are subject to pharmacovigilance and ongoing safety/labeling compliance (Guideline on the Regulation of Therapeutic Products in New Zealand - Part 8, 2020).
  • Medsafe actively monitors, records adverse events, and may recall products or amend consents if new safety data emerges.